Clinical and pharmacological group: & nbsp

Enzymes and antiferments

Included in the formulation
  • Collalisin®
    lyophilizate locally 
    SPbNIIVS FMBA, FSUE     Russia
  • АТХ:

    D.03.B.A   Proteolytic enzymes

    D.03.B.A.03   Bromelaines

    Pharmacodynamics:

    Destruction of collagen - the main component of connective tissue, while viable muscles, granulation tissue and epithelium remain intact. With purulent wounds promotes rapid clearance from non-viable tissues and exudate, an earlier appearance of granulation tissue and epithelization. Prevention of development of coarse (type of keloid) scars, contributes to the preservation of the function of the joints. When aqueous solutions are applied to keloid tissue, a lytic effect occurs, the degree of which depends on the duration of exposure.

    Pharmacokinetics:

    Not studied.

    Indications:

    Wounds, ulcerated surfaces with necrotic tissues.

    XIX.T08-T14.T14.1   Open wound of unspecified area of ​​the body

    Contraindications:

    Hypersensitivity, pregnancy, lactation.

    Carefully:

    Children under 18 years.

    Pregnancy and lactation:

    Category FDA not determined.

    Contraindicated in pregnancy. For the duration of treatment, breastfeeding should be discontinued.

    Dosing and Administration:

    Locally, apply directly to the wound 1-2 times a day.

    Side effects:Possible: pain, burning, hyperemia in the place of application of the ointment.
    Overdose:

    Not described.

    Interaction:

    Antiseptics, heavy metals, detergents, soaps weaken the activity of collagenase.

    Do not combine with tirotricin, gramicidin, tetracyclines.

    Special instructions:

    If there is an infection, antibacterial therapy should be used.

    Instructions
    Up